Diabetes affects 285 million individuals worldwide ([@B1]), and diabetic retinopathy (DR) is the leading cause of blindness in the working-age population in most developed countries ([@B2]). Although it has been suggested that endothelial dysfunction may underlie the pathogenesis of DR ([@B3]), the few clinical and epidemiologic studies to date have found inconsistent associations of DR with indirect serum markers of endothelial function (e.g., soluble vascular adhesion molecule-1) ([@B4]--[@B9]) or brachial flow--mediated dilation (FMD) ([@B10]--[@B13]), a more direct measurement of endothelial dysfunction ([@B14]).

Drug delivery to the skin by iontophoresis, accompanied by laser Doppler technology to measure microvascular flow, has been validated as a measure of endothelial function in the skin microcirculation ([@B15]). Responses of the skin microcirculation to sodium nitroprusside (SNP) and acetylcholine (ACh) are measures of endothelium-independent and endothelium-dependent responses, respectively. Studies have shown a strong correlation between endothelial function assessed by FMD of the brachial artery and ACh increase in skin blood flow (*r* = 0.92, *P* \< 0.0001) ([@B16]). Further study has shown that impaired skin microvascular response is associated with a range of cardiovascular risk factors and diseases ([@B15]).

In this study, we examined the relationship of DR with skin microvascular dysfunction as measured by iontophoresis and laser Doppler flowmetry in a clinical sample of patients with diabetes. Our aim was to establish whether DR was associated with systemic microvascular dysfunction evidenced in the skin and whether this was primarily driven by endothelial dysfunction.

RESEARCH DESIGN AND METHODS {#s5}
===========================

We conducted a case--control study of DR among 224 individuals with diabetes, consisting of 85 with type 1 diabetes and 139 with type 2 diabetes. Participants were recruited from the diabetic eye clinics at the International Diabetes Institute, Melbourne, Australia, between October 2006 and April 2008. Detailed examination of the participants has been previously reported ([@B3]). In brief, individuals with known diabetes who were seen at the diabetic eye clinics and treated with oral hypoglycemic mediations and/or insulin were eligible. Participants were excluded if aged older than 70 years, currently pregnant, had a previous mastectomy (with axillary clearance), previous vitreal surgery, had an arteriovenous fistula on the arm/forearm, a history of skin cancer on the arm/forearm, epilepsy, glaucoma, and/or had cataract on examinations for this study.

All participants underwent a standardized clinical examination, analysis of blood chemistry, retinal photographs, and assessment of skin microvascular dysfunction. Tenets of the Declaration of Helsinki were followed, institutional review board approval was granted, and written informed consent was obtained from all participants.

Skin microcirculation endothelial function {#s6}
------------------------------------------

Skin microcirculation endothelial function was measured using a laser Doppler flowmetry technique that assessed the skin microcirculation responses to iontophoresis of SNP and ACh ([@B15]). Iontophoresis delivers the SNP and ACh vasodilators across the skin using a weak electrical current, with blood flow measured by laser Doppler flowmetry. Participants were seated comfortably in a room with an ambient temperature of 20--23°C. All tests were performed on both forearms.

A battery-powered current stimulator (WPI 502R) provided a direct current for drug iontophoresis. A laser Doppler flow meter (Moor Instruments, Axminster, U.K.) was used to measure the skin blood flux (in arbitrary perfusion units). Flux is a function of the volume of blood multiplied by velocity. Vascular responses to SNP (endothelial-independent vasodilator) and ACh (endothelial-dependent vasodilator) were recorded. SNP 1% and ACh 1% solutions in distilled water were used for iontophoresis. Doses of the vasoactive drugs were expressed as a total charge in millicoulombs (mC), determined by the product of current (0.2 mA) and stimulus duration (seconds). Doses of 16 mC (0.2 mA × 80 s) were used. "Mean baseline flux" was the mean flux measured over 120 s before iontophoresis, and "mean response flux" was the mean flux over 240 s after the iontophoresis. The responses to SNP or ACH were calculated as: \[Mean response flux -- Mean baseline flux\]/\[Mean baseline flux\].

Assessment of DR {#s7}
----------------

DR was graded from fundus photographs at the Centre for Eye Research Australia by graders masked to clinical details ([@B3]). A DR severity score was assigned for each eye using a modification of the Airlie House Classification system ([@B17]). Presence of DR was defined as any retinopathy signs in the right or left eye.

Assessment of other risk factors {#s8}
--------------------------------

A detailed questionnaire was used to obtain participant information, including medical history, current cigarette smoking, and the use of hypertension and dyslipidemia medications. Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of antihypertensive medications. Dyslipidemia was defined as cholesterol \>5.5 mmol/L, or triglyceride \>2.0 mmol/L, or current use of lipid-lowering medications. Height and weight were measured to determine BMI. Fasting blood samples were drawn from participants at suburban pathology centers for fasting blood glucose (FBG), cholesterol, and triglyceride levels within 2 weeks of the eye testing.

Statistical analysis {#s9}
--------------------

Mean responses to iontophoresis of SNP and ACh of the right and left arms were used. When only one was arm measured, responses in that arm were used. Responses were dichotomized by the median values into upper and lower half (50%) for analyses. Multiple logistic regression models were used to estimate odds ratios (ORs) and 95% CI for the presence of DR according to whether subjects were in the upper or lower half of the responses to iontophoresis. We adjusted for age and sex (model 1), and further adjusted for duration of diabetes, FBG level, SBP, fasting cholesterol and triglyceride levels, current smoking status, and use of antihypertensive and dyslipidemia medications (model 2). Responses to SNP and ACh were modeled separately initially, followed by further adjustment for ACh response in models assessing SNP response, or SNP response in models assessing ACh response (model 3).

Finally, responses to SNP and ACH were assessed jointly by classifying four groups of responses, comprising group 1: those with responses in the upper half for both SNP and ACh (reference group), group 2: those with responses in the lower half for SNP but in the upper half for ACh, group 3: those with responses in the lower half for ACh but in the upper half for SNP, and group 4: those with responses in the lower half for both SNP and ACh. Analyses were performed in Stata 10.1 software (StataCorp, College Station, TX).

RESULTS {#s10}
=======

The participants were of white racial background. Selected characteristics of the 224 participants with diabetes, and of those with (*n* = 144) and without (*n* = 80) DR, are summarized in [Table 1](#T1){ref-type="table"}. Mean age was 56.5 ± 11.8 years, 59.4% were men, and 64.3% had DR. Those with DR had a longer duration of diabetes, a higher SBP, and were more likely to have hypertension. In addition, those with DR also had reduced responses to iontophoresis of SNP and ACh.

###### 

Participant characteristics comparing subjects with and without DR

                              All subjects   DR present     DR absent      
  --------------------------- -------------- -------------- -------------- ---------
  Male sex                    133 (59.4)     41 (51.3)      92 (63.9)      0.07
  Smoking                                                                  
   Current                    16 (7.1)       14 (9.7)       2 (2.5)        0.11
   Past                       88 (39.3)      57 (39.6)      31 (38.8)      
   Never                      120 (53.6)     73 (50.7)      47 (58.8)      
  Hypertension                137 (61.2)     99 (68.8)      38 (47.5)      0.002
  Dyslipidemia                122 (54.5)     83 (57.6)      39 (48.8)      0.20
  Age (years)                 56.5 ± 11.8    57.4 ± 10.9    54.8 ± 13.3    0.11
  Diabetes duration (years)   16.2 ± 10.5    18.6 ± 10.7    11.8 ± 8.67    \<0.001
  Blood pressure (mmHg)                                                    
   Systolic                   128 ± 14.5     129.8 ± 14.9   124.8 ± 13.2   0.01
   Diastolic                  76.1 ± 8.9     75.9 ± 9.2     76.5 ± 8.4     0.64
  BMI (kg/m^2^)               30.4 ± 6.3     30.9 ± 6.4     29.8 ± 5.6     0.24
  Hemoglobin A~1c~ (%)        7.9 ± 1.4      7.9 ± 1.1      7.8 ± 2.1      0.68
  Glucose (mmol/L)            9.2 ± 3.7      9.3 ± 3.6      8.8 ± 4.0      0.50
  Cholesterol (mmol/L)        4.6 ± 1.1      4.5 ± 1.0      4.6 ± 1.3      0.51
  Triglyceride (mmol/L)       1.6 ± 1.1      1.7 ± 1.1      1.5 ± 0.9      0.44
  SNP                         5.0 ± 2.34     4.63 ± 2.10    5.58 ± 2.58    0.005
  ACh                         6.41 ± 3.15    5.92 ± 3.07    7.16 ± 3.13    0.007

Data are presented as *n* (%) or as mean ± SD.

\*Comparing those with and without DR in those with diabetes.

Individuals with reduced responses to iontophoresis of SNP or ACh were more likely to have DR (SNP: 70.3 vs. 50.5%; ACh: 71.0 vs. 50.5%; [Fig. 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). After adjusting for age, sex, duration of diabetes, FBG, SBP, fasting cholesterol and triglyceride levels, current smoking status, and use of antihypertensive and lipid-lowering medications, reduced responses to SNP or ACh were associated with increased odds of DR (SNP: OR 2.33 \[95% CI 1.09--5.01\], *P* = 0.03; ACh: 2.20 \[1.05--4.61\], *P* = 0.04, comparing lower vs. upper half of responses of each test, respectively). This was no longer statistically significant after further adjusting for ACh response in models assessing SNP response, or vice versa (model 3).

![Scatterplots of the responses to SNP and ACh in people with diabetes. The black circle (●) indicates individuals with diabetic retinopathy.](1389fig1){#F1}

###### 

Association between skin iontophoretic responses to SNP and ACh with DR

  Groups                                            Range        *N*   DR          Model 1[\*](#t2n1){ref-type="table-fn"}   *P*         Model 2[†](#t2n2){ref-type="table-fn"}   *P*         Model 3[‡](#t2n3){ref-type="table-fn"}   *P*
  ------------------------------------------------- ------------ ----- ----------- ----------------------------------------- ----------- ---------------------------------------- ----------- ---------------------------------------- ------
  Response to                                                                                                                                                                                                                          
   SNP (endothelium-independent**)**                                                                                                                                                                                                   
    Upper half                                      4.70--17.2   95    48 (50.5)   1.0                                       ---         1.0                                      ---         1.0                                      ---
    Lower half                                      1.46--4.67   101   71 (70.3)   **2.20 (1.19**--**4.07)**                 **0.01**    **2.33 (1.09**--**5.01)**                **0.03**    2.14 (0.96--4.77)                        0.06
   ACh (endothelium-dependent)                                                                                                                                                                                                         
    Upper half                                      6.08--20.5   97    49 (50.5)   1.0                                                   1.0                                                  1.0                                      ---
    Lower half                                      1.26--6.06   99    71 (71.0)   **2.25 (1.23**--**4.12)**                 **0.008**   **2.20 (1.05**--**4.61)**                **0.04**    1.98 (0.91--4.28)                        0.08
  Both SNP and ACh[§](#t2n4){ref-type="table-fn"}                                                                                                                                                                                      
   Upper half of both SNP and ACh                   ---          68    34 (50)     1.0                                                   1.0                                      ---         ---                                      ---
   Lower half of SNP, upper half of ACh             ---          29    15 (51.7)   1.01 (0.41--2.49)                         0.98        0.84 (0.28--2.46)                        0.74        ---                                      ---
   Upper half of SNP, lower half of ACh             ---          27    14 (51.9)   1.01 (0.41--2.46)                         0.99        0.86 (0.28--2.63)                        0.79        ---                                      ---
   Lower half of both SNP and ACh                   ---          72    56 (77.8)   **3.30 (1.54**--**7.10)**                 **0.002**   **3.86 (1.45--10.3)**                    **0.007**   ---                                      ---

Boldface type indicates significant interaction between responses to SNP and ACh (*P* for interaction term \< 0.05).

\*Model 1: Adjusted for age and sex.

†Model 2: Adjusted for covariates in model 1 plus diabetes duration, FBG, total cholesterol and triglyceride levels, BMI, SBP, current smoking status, and use of antihypertensive and lipid-lowering medications.

‡Model 3: Adjusted for covariates in model 2 plus ACh response with SNP response, or SNP response with ACh response.

§Participants divided into four groups according to response to SNP and ACh (see text).

Subjects with reduced responses to both SNP and ACh, compared with those with both responses above the median values, had higher odds of DR (OR 3.86 \[95% CI 1.45--10.3\], *P* = 0.007) after multivariable adjustment. Most of the diabetic individuals were those with responses in the upper half for both SNP and ACh (group 1) and in the lower half for both SNP and ACh (group 4).

A separate analysis by those with type 1 and type 2 diabetes showed the association of DR and reduced iontophoretic responses remained significant only in those with type 2 diabetes, with the SNP responses (upper vs. lower half), and those with reduced responses to both SNP and ACh ([Supplementary Table A1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1985/-/DC1)). There were only 85 individuals with type 1 and 139 with type 2 diabetes.

CONCLUSIONS {#s11}
===========

This study demonstrated that among patients with diabetes, those with DR had a reduction in the skin microvascular responses to iontophoresis of both SNP (endothelium-independent response) and ACh (endothelium-dependent response). Patients with a reduction in responses to SNP or ACh were two times more likely to have DR, whereas those with a reduction in responses to both SNP and ACh were four times more likely to have DR. These associations were independent of major risk factors for diabetes and cardiovascular diseases, including duration of diabetes, glycemia, and blood pressure. Our findings suggest that DR is closely linked with systemic vascular disease processes, as evidenced in the skin, that reflect a combination of endothelium-dependant dysfunction and endothelium-independent mechanisms.

To our best knowledge, this is the first study to examine DR and changes in skin microcirculation, as measured by laser Doppler flowmetry in response to iontophoresis of SNP and ACh. ACh is known to stimulate nitric oxide (NO) production in endothelial cells (endothelium-dependent vasodilation) ([@B18],[@B19]), whereas SNP is an NO donor to vascular smooth muscle cells (endothelium-independent vasodilation). Theoretically, a reduction in vascular response in ACh alone, with no concurrent reduction in SNP response, would be indicative of endothelial dysfunction. Most of the diabetic individuals in our study were those with responses for both SNP and ACh in the upper half (group 1) and in the lower half (group 4). Owing to the relatively small sample sizes, we were unable to adequately compare those with high SNP and high ACh responses versus those with high SNP but low ACh responses (i.e., a comparison of endothelial function). In addition, our study could not discriminate whether abnormal responses were due to decreased production of NO, increased destruction or inactivation of NO, or decreased vascular smooth muscle cell responsiveness to it.

Nevertheless, our finding of an association of DR with a reduction in skin responses to both ACh and SNP implies a likely more complex mechanism in DR pathogenesis than pure endothelial dysfunction alone. This may explain the inconsistent findings of DR and systemic measures of endothelial dysfunction such as serum markers (e.g., soluble vascular adhesion molecule-1) ([@B4]--[@B9]), and brachial FMD ([@B10]--[@B13]).

Our observation that DR is associated with a combined reduction in responses to endothelial-dependent and independent vasodilatation may also reflect microvascular sclerosis (i.e., a more physical loss of vasodilator reserve) ([@B19],[@B20]). However, the overall vascular dysfunction probably involves a complex interaction between functional and structural abnormalities in the microcirculation ([@B21],[@B22]). We have previously shown that DR may be associated with retinal endothelial dysfunction in the same cohort ([@B3]) and that this may be due to differences in the vascular beds. However, our finding of DR with abnormal systemic microcirculation may provide some insights into the relationships between DR and increased risks of cardiovascular diseases, including new measures of subclinical cardiovascular disease such as coronary artery calcification and cardiac remodeling ([@B23]).

The strengths of this study include the photographic assessment of DR using standardized grading protocols, and one person (T.T.N.), masked to DR status, performed and supervised the assessment of the skin microcirculation responses to SNP and ACh using laser Doppler flowmetry.

Limitations of this study should also be noted. First, the cross-sectional nature provides no temporal information on the associations reported. Second, our findings are only applicable to individuals with diabetes, not pregnant, and aged 70 years or younger. Third, the analysis of the subgroups of level of DR was not feasible due to the small number in each group, and thus, our study was not sufficiently powered to address this. In addition, our study was not sufficiently powered to analyze the relationships in type 1 and type 2 diabetes separately, with only 85 with type 1 and 139 with type 2 diabetes. These are possible future study questions.

Limitation of the method used to assess endothelial function includes the use of single-point laser Doppler flowmetry to assess responses to iontophoresis of SNP and ACh. Laser Doppler flowmetry is less reliable and reproducible than laser Doppler imaging systems, which measure perfusion over a larger area and produce a detailed perfusion map ([@B15]). In addition, comparison with future studies would be difficult owing to differences in apparatus, iontophoresis protocols, and environmental conditions. A standardization of techniques would help to resolve this.

In conclusion, we demonstrated an association of DR with reduced responses to iontophoresis of both SNP and ACh in the skin microcirculation. Our findings suggest associations of DR with systemic microangiopathy reflect a combination of endothelial dysfunction and endothelial function-independent mechanisms. These findings provide further insights into possible mechanisms of systemic risk factors on development of DR.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1985/-/DC1>.
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